Compare RAYA & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | PLUR |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 31.5M |
| IPO Year | 2022 | N/A |
| Metric | RAYA | PLUR |
|---|---|---|
| Price | $3.95 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 29.4K | ★ 48.8K |
| Earning Date | 04-17-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | $1,326,000.00 |
| Revenue This Year | $20.95 | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.78 | ★ 121.74 |
| 52 Week Low | $3.13 | $2.82 |
| 52 Week High | $736.99 | $7.13 |
| Indicator | RAYA | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 39.31 |
| Support Level | $3.64 | $2.90 |
| Resistance Level | $4.04 | $3.42 |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 23.31 | 15.56 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.